nach oben

Drugs in R&D

Erschienen in:

01.01.2005 | Adis R&D Profile

Lasofoxifene

CP 336156, CP-336156

Erschienen in: Drugs in R&D | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Excerpt

Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). It has the bone-sparing and cardioprotective effects of estrogen, but lacks estrogen’s uterine cancer risk. Lasofoxifene is under development with Ligand Pharmaceuticals and Pfizer (formerly Parke-Davis) for the prevention of postmenopausal osteoporosis and breast cancer. …

Ligand Pharmaceuticals, Royalty Pharma. Ligand, Royalty Pharma Amend SERM Royalty Agreement; Royalty Pharma Accelerates and Increases Royalty Purchase to $32.5 Million as Substitute for Final Two Options. Media Release: 9 Nov 2004. Available from URL: http://www.ligand.com

Ligand Pharmaceuticals Incorporated. Ligand Earns Milestone as Pfizer Submits NDA for Lasofoxifene for Osteoporosis; First of Three Phase III SERM Products Advancing Prospects of Future Royalties. Media Release: 16 Sep 2004. Available from URL: http://www.ligand.com

Pfizer Inc. Pfizer Sees Strong Prospects from the Industry’s Premier R&D Pipeline and Expanding New Product Opportunities. Media Release: 30 Nov 2004. Available from URL: http://www.pfizer.com

Rosati RL, Jardine PDS, Cameron KO. Discovery and sar of a potent non-steroidal estrogen agonist, CP-336,156. 212th American Chemical Society National Meeting 212: abstr. 205, 25 Aug 1996

Pfizer cancer treatment portfolio has four candidates nearing clinic. FDC Reports — Pink Sheet — Prescription Pharmaceuticals and Biotechnology 60: 19, 16 Nov 1998

McClung M, Weiss S, Moffett AH, et al. A study of lasofoxifene, a next generation SERM, versus raloxifene, in preventing bone loss in postmenopausal women. Arthritis and Rheumatism 50 (Suppl.): 669, No. 9, Sep 2004

Ke HZ, Oi H, Crawford DT. A new selective estrogen receptor modulator, CP-336,156, preserves bone mass and bone strength, decreases total serum cholesterol without causing prostate hypertrophy in a model of male osteoporosis. Bone 23 (Suppl.): 183, No. 5, 1998

Rosati RL, Da Silva Jardine P, Cameron KO. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. Journal of Medicinal Chemistry 41: 2928–2931, 30 Jul 1998PubMedCrossRef

Ke HZ, Li M, Pan LC, et al. Combined administration of a growth hormone secretagogue and a new selective estrogen receptor modulator increases bone and muscle mass and decreases total serum cholesterol in ovariectomized rats. Bone 23 (Suppl.): 390, No. 5, 1998

10.

Ke HZ, Qi H, Chidsey-Frink KL. et al. Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. Journal of Bone and Mineral Research 15 (Suppl. 1): 310 (plus poster), Sep 2000

11.

Cole HW, Adrian MD, Shetler PK, et al. Comparative pharmacology of high potency selective estrogen receptor modulators (SERMs): LY353381 HCL and CP336,156. Journal of Bone and Mineral Research 12: 349, 1997CrossRef

12.

Bell J. SERMs: benefits for bone and breast (ASBMR 2000). Scientific Meetings News: 2 Oct 2000

Titel: Lasofoxifene
CP 336156, CP-336156
Publikationsdatum: 01.01.2005
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 1/2005
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200506010-00008

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Lasofoxifene

CP 336156, CP-336156

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Histrelin Hydrogel Implant — Valera

Effects of Concurrent Therapy with Policosanol and Omega-3 Fatty Acids on Lipid Profile and Platelet Aggregation in Rabbits

Erythrocyte Glutathione Levels in Lithium-Induced Hypothyroidism

Pharmacokinetics and Pilot Efficacy of a Mesalazine Rectal Gel in Distal Ulcerative Colitis

Glufosfamide

Utilisation of Human Pharmacology Studies with Biomarkers for New Drug Applications in Japan